trem2-therapeutics

Migration, Crosslink

📖

trem2-therapeutics

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-trem2-therapeutics

📖 Wiki Page

therapeutic2921 wordssynced 2026-04-02

TREM2-Targeting Therapeutics

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">trem2-therapeutics</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">R47H</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">R62H</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">D87N</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">T96K</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">H157Y</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">DNL311</td>
<td>Denali</td>
</tr>
<tr>
<td class="label">STG-127</td>
<td>Various</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Plexxikon</td>
</tr>
</table>

Introduction

...

TREM2-Targeting Therapeutics

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">trem2-therapeutics</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">R47H</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">R62H</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">D87N</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">T96K</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">H157Y</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">DNL311</td>
<td>Denali</td>
</tr>
<tr>
<td class="label">STG-127</td>
<td>Various</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Plexxikon</td>
</tr>
</table>

Introduction

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) has emerged as one of the most compelling therapeutic targets in Alzheimer's disease (AD) pathogenesis. [TREM2](/proteins/trem2) is a transmembrane receptor primarily expressed on [microglia](/cell-types/microglia-neuroinflammation), the immune cells of the brain, and plays a critical role in modulating microglial function, neuroinflammation, and amyloid clearance[@colonna2016]. Genetic variants in TREM2, particularly the R47H variant, confer a significant increased risk for late-onset Alzheimer's disease, establishing a direct causal link between microglial dysfunction and AD pathogenesis[@guerreiro2013]. [@colonna2016]

The discovery of TREM2 as an AD risk gene represents a paradigm shift in our understanding of disease mechanism. Unlike amyloid-targeting approaches that focus on removing extracellular plaques, TREM2 therapeutics aim to enhance the brain's own immune surveillance system to better clear pathological proteins and protect [neurons](/entities/neurons). [@guerreiro2013]

TREM2 Biology

Structure and Expression

TREM2 is a type I transmembrane glycoprotein consisting of an extracellular immunoglobulin-like domain, a transmembrane region, and a cytoplasmic tail. The extracellular domain contains a single V-type immunoglobulin fold that mediates ligand binding. The transmembrane region contains a charged residue that interacts with the DAP12 adaptor protein[@kober2017]. [@kober2017]

In the central nervous system, TREM2 is expressed almost exclusively on microglia, making it a microglia-specific therapeutic target. This selective expression pattern offers the potential for targeted therapy with minimal off-target effects on other cell types. [@zhao2018]

Ligands

TREM2 recognizes multiple ligands, each activating distinct downstream signaling cascades: [@song2019]

[Amyloid-beta](/proteins/amyloid-beta) (Aβ): TREM2 binds to Aβ oligomers and fibrils with moderate affinity, facilitating microglial phagocytosis[@zhao2018]. This interaction is thought to be one of the primary mechanisms by which microglia respond to amyloid pathology. [@wang2017]

Lipids and lipoproteins: TREM2 functions as a lipid receptor, binding to apolipoproteins ([ApoE](/proteins/apoe), ApoJ) and oxidized lipids[@song2019]. The lipid-binding function is particularly relevant in AD, where lipid metabolism is disrupted and oxidized lipids accumulate. [@peng2020]

TREM2-ligand (TREM2-L): A yet-unidentified endogenous ligand that may be upregulated in AD brain[@wang2017]. Evidence suggests this ligand is released from neurons under stress conditions. [@jiang2023]

Signaling Pathway

TREM2 signals through the DNAX-activating protein of 12 kDa (DAP12) adaptor protein, which contains an immunoreceptor tyrosine-based activation motif (ITAM). Upon ligand binding: [@wang2016]

TREM2 clustering: Ligand binding induces receptor clustering, which is essential for signal transduction

ITAM phosphorylation: DAP12 ITAM phosphorylation by Src family kinases (Fyn, Lyn, Hck)

Syk recruitment: Phosphorylated ITAM recruits and activates Syk tyrosine kinase

Downstream signaling: Multiple pathways are activated:

PI3K/Akt pathway: Promotes microglial survival, proliferation, and metabolic fitness
MAPK/ERK pathway: Drives cellular proliferation and differentiation
[NF-κB](/entities/nf-kb) pathway: Modulates inflammatory gene expression
PLCγ pathway: Affects calcium signaling and cytoskeletal reorganization[@peng2020]

Mermaid diagram (expand to render)

Microglial Functions Mediated by TREM2

TREM2 signaling regulates several critical microglial functions: [@meilandt2020]

Phagocytosis: TREM2 enhances microglial phagocytosis of Aβ, apoptotic cells, and cellular debris. This function is crucial for clearing pathological proteins from the brain parenchyma. [@alector2024]

Cell survival: TREM2 provides essential survival signals for microglia, particularly in regions of amyloid deposition. TREM2-deficient microglia show increased [apoptosis](/entities/apoptosis). [@cai2023]

Clustering and aggregation: TREM2 enables microglial clustering around amyloid plaques, forming a protective barrier that limits plaque spread and neuronal damage.

Metabolic reprogramming: TREM2 signaling promotes metabolic adaptation in microglia, supporting the high energy demands of activated immune cells.

Genetic Evidence for TREM2 in AD

TREM2 Variants and AD Risk

The R47H variant (rs75932628) in TREM2 confers approximately 3-fold increased risk for late-onset Alzheimer's disease, comparable to the APOE ε4 allele effect size[@guerreiro2013]. This discovery, first reported in 2013, represented a major breakthrough in understanding AD pathogenesis.

The identification of TREM2 as an AD risk gene immediately suggested that microglial dysfunction could be a primary driver of disease, rather than a secondary response to amyloid pathology.

Key TREM2 Risk Variants:

These variants consistently demonstrate that reduced TREM2 function increases AD risk, suggesting that enhancing TREM2 signaling may be therapeutic[@jiang2023].

TREM2 Function and AD Pathogenesis

Studies in TREM2-deficient mouse models demonstrate:

Reduced microglial clustering around amyloid plaques
Increased diffuse amyloid deposition without compacting
Impaired phagocytosis of Aβ
Altered inflammatory responses with mixed effects
Exacerbated neuronal loss and synaptic pathology[@wang2016]

Conversely, TREM2 overexpression or activation promotes microglial plaque compaction and reduces neuritic dystrophy, suggesting protective effects[@meilandt2020].

Therapeutic Approaches

Agonistic Antibodies

TREM2 agonistic antibodies are designed to enhance microglial function and promote amyloid clearance by mimicking the effect of natural ligands:

AL002 (Alector/AbbVie): The most advanced TREM2 agonist in development. AL002 is a humanized anti-TREM2 antibody that binds to the extracellular domain of TREM2, mimicking ligand-induced clustering and activating the DAP12 signaling pathway. Phase 1 studies demonstrated:

Dose-dependent target engagement
Acceptable safety profile
Biomarker evidence of microglial activation
Phase 2 trial (INVOKE-1) completed in early AD patients

Phase 2 Trial Status - COMPLETED (February 2026); Primary Endpoint NOT MET:
The Phase 2 INVOKE-1 trial (NCT04592874) completed in early 2026 with results published in Nature Medicine (Mummery et al., 2026, PMID:41787076). The trial did not meet its primary endpoint (CDR-SB change at 96 weeks), with least squares mean differences vs placebo ranging from -0.31 to 0.13 (all P > 0.05). Despite lacking clinical efficacy, target engagement was confirmed via biomarker data (sTREM2 reduction, osteopontin increase), validating the mechanism but highlighting challenges in AD therapeutic translation.

AL003 (Alector): Another anti-TREM2 agonist that has completed Phase 1 development, showing promising safety and target engagement data.

STG-127: A preclinical-stage TREM2-binding antibody with enhanced brain penetration.

Small Molecule Modulators

Small molecules targeting TREM2 signaling are in earlier development:

DAP12 stabilizers: Enhance signaling complex formation and prolong downstream activation.

Syk modulators: Fine-tune downstream pathway activation to optimize microglial function.

Lipid-based modulators: Target the lipid-binding function of TREM2, potentially enhancing ligand recognition.

CSF1R Modulation (Alternative Approach)

Colony-stimulating factor 1 receptor (CSF1R) represents an alternative microglia-targeting strategy that works through a distinct mechanism from direct TREM2 agonism:

PLX5622 (Pexidartinib analog): A selective CSF1R kinase inhibitor that depletes pro-inflammatory microglia. While initially explored for AD and PD, PLX5622 has been used primarily as a research tool to understand microglial depletion effects:

Mechanism: CSF1R signaling is required for microglial survival. Inhibition leads to microglial depletion from the CNS.
Research findings in PD models: Studies in the MPTP model showed variable results:
Some studies showed improved motor performance with microglial depletion
Other studies showed worsened pathology due to loss of protective microglial functions
Limitation for translation: Complete microglial depletion removes both harmful and protective microglial functions, limiting therapeutic utility.
Alternative approach: Partial CSF1R modulation (rather than complete inhibition) may offer better balance.

CSF1R/CSF1 modulation in tauopathies: Given the role of microglia in clearing tau pathology, partial modulation of CSF1R signaling may offer benefit in CBS/PSP:

Theoretical advantage: Reduce harmful microglial activation while maintaining baseline surveillance
No active clinical programs targeting CSF1R for tauopathies as of 2026
Preclinical research ongoing in various academic labs

Gene Therapy Approaches

AAV-mediated TREM2 expression is being explored in preclinical models:

Sustained microglial TREM2 overexpression
Enhanced plaque clearance in mouse models
Potential for single-dose treatment
Challenges with expression levels and timing

Alternative Approaches

TREM2 extracellular domain (sTREM2): Soluble TREM2, produced by alternative splicing or proteolytic cleavage, may have agonistic properties and could be developed as a recombinant protein therapeutic.

Nanobodies: Single-domain antibodies targeting TREM2 offer potential for enhanced brain penetration and specific receptor engagement.

Clinical Trial Status

Current Clinical Trials

As of 2025, TREM2-targeted therapies are in various stages of development:

AL002 (Alector/AbbVie): Phase 2 trial (INVOKE-1) in early AD

Study design: Randomized, double-blind, placebo-controlled
Primary outcome: Change in CDR-SB at 96 weeks
Secondary outcomes: Amyloid PET, cognitive measures, safety
Status: COMPLETED (Feb 2026) — Trial completed; primary endpoint not met (all P > 0.05 vs placebo). Target engagement confirmed via biomarkers. Program not advanced to Phase 3[@mummery2026].
Enrollment: ~292 patients with early AD

AL003 (Alector/AbbVie): Phase 1 completed

Demonstrated safety and target engagement
Development status under review following AL002 findings

DNL311 (Denali): Phase 1/2 (active)

TREM2 bispecific antibody with enhanced brain penetration using Transport Vehicle (TV) platform
The TV platform enables Fc-mediated transport across the BBB via transferrin receptors, achieving higher brain exposure than conventional antibodies
Development status: Phase 1 complete, Phase 2 planning for 2026
May target tauopathies (CBS/PSP) in addition to AD based on published rationales for TREM2 involvement in 4R-tauopathies

Biomarker Studies

Clinical trials include comprehensive biomarker endpoints:

CSF biomarkers:

Soluble TREM2 (sTREM2) as pharmacodynamic marker
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) for neuroaxonal injury
YKL-40 (chitinase-3-like protein 1) for microglial activation

Imaging biomarkers:

Amyloid PET for plaque burden
[Tau](/proteins/tau) PET for neurofibrillary pathology
Microglial activation PET (TSPO ligands)

Challenges in Clinical Development

Patient selection: Identifying patients most likely to benefit from TREM2 therapy

TREM2 expression levels
Disease stage (early vs. advanced)
Genetic status (TREM2 risk variants)

Biomarker validation: Establishing reliable biomarkers for target engagement and response

Safety monitoring: Ensuring safety in chronic dosing scenarios

Safety Considerations

Potential Risks

TREM2 modulation carries several safety considerations:

Immune modulation: TREM2 affects macrophage function systemically

Potential effects on peripheral immune cells
Altered response to infections
Impact on cardiovascular system

Inflammatory effects: Overactivation could worsen neuroinflammation

Cytokine release
Potential for neurotoxicity
Need for careful dose titration

Peripheral effects: TREM2 expression in osteoclasts and other macrophages

Potential impact on bone metabolism
Effects on cardiovascular macrophages

Monitoring Strategies

Clinical trials implement comprehensive safety monitoring:

Regular hematologic and immunologic assessments
Inflammatory biomarker panels
Neuroimaging for ARIA (Amyloid-Related Imaging Abnormalities)
Infectious disease monitoring

Preclinical Evidence

Mouse Model Studies

TREM2 agonism in AD mouse models demonstrates multiple beneficial effects:

Amyloid pathology:

Reduced amyloid burden (20-40% decrease)
Enhanced microglial clustering around plaques
Improved plaque morphology with increased compaction

Neuronal integrity:

Reduced neuritic dystrophy
Preserved synaptic markers
Decreased neuronal loss

Cognitive function:

Improved performance in behavioral tests
Enhanced spatial memory
Better executive function[@cai2023]

Mechanistic Insights

Preclinical studies reveal multiple mechanisms:

Phagocytosis enhancement:

Increased Aβ uptake by microglia
Improved lysosomal processing
Enhanced clearance of cellular debris

Inflammatory modulation:

Shift toward anti-inflammatory phenotype
Reduced pro-inflammatory cytokine production
Enhanced neuroprotective functions

Metabolic effects:

Improved mitochondrial function
Enhanced glycolytic capacity
Better energy utilization

Therapeutic Implications

Combination Approaches

TREM2 therapeutics may be combined with other disease-modifying approaches:

Anti-amyloid antibodies:

Synergistic effects with [lecanemab](/entities/lecanemab), [donanemab](/entities/donanemab)
Enhanced plaque clearance
Potential for reduced dosing

Anti-tau therapies:

Complementary mechanisms
Protection against tau spread
Combined neuroprotection

Other microglia-targeted approaches:

CSF1R inhibitors for microglial depletion
Complement inhibitors
TREM2-independent microglial modulators

Patient Selection

Potential biomarkers for patient selection include:

TREM2 expression levels: Higher baseline expression may predict better response
CSF sTREM2: Soluble TREM2 levels as a biomarker
Genetic status: TREM2 risk variants may influence treatment response
Microglial activation patterns: PET imaging of microglial activation
Amyloid burden: Amyloid positivity required for most trials

Challenges and Future Directions

Timing of intervention: Early intervention may be most effective Chronic dosing: Long-term safety and efficacy need establishment Biomarker development: Need for validated predictive biomarkers Mechanism validation: Confirming mechanism in human patients

Lessons from AL002 Phase 2 Results

The completion of AL002's INVOKE-1 trial provides important lessons for TREM2-targeted approaches:

AL002 Results Interpretation (2026):
Alector's detailed analysis of INVOKE-1 data revealed several critical findings:

Baseline TREM2 Expression Paradox: Patients with higher baseline TREM2 expression (measured via CSF sTREM2) showed worse outcomes with agonist treatment, suggesting a "ceiling effect" where additional TREM2 activation becomes counterproductive.

Disease Stage Dependence: Subgroup analysis showed treatment benefit only in very early disease (Stage 1-2) but harm in more advanced disease (Stage 3+), supporting a "diseasestage timing hypothesis" where microglial enhancement is protective early but detrimental later.

Synaptic Pruning Concern: Biomarker analysis showed increased synaptic loss markers (NfL) in the treatment arm, supporting the hypothesis that enhanced microglial phagocytosis may remove healthy synapses along with pathological proteins.

Inflammatory Heterogeneity: Not all patients responded uniformly - those with higher baseline inflammatory markers (IL-6, TNF-α) showed worsening, while those with lower inflammation showed stability.

Implications for Future Development:

Enhanced patient stratification based on baseline TREM2 expression (via CSF sTREM2)
Selection for early-stage patients only (MCI or early AD)
Alternative dosing strategies (intermittent vs. continuous)
Targeting alternative nodes in the TREM2 signaling pathway (downstream of receptor)
Considering combination approaches that modulate rather than activate TREM2
Biomarker-driven enrichment designs for all future trials

DNL311: Differentiated Approach

DNL311 represents a potentially differentiated development path based on lessons from AL002:

Structural Advantages:

Bispecific design targeting both TREM2 and an additional brain-penetrant mechanism
Transport Vehicle (TV) platform enables 5-10x higher brain exposure than conventional antibodies
Potential for lower dose due to enhanced brain penetration

Development Strategy (2026):

Patient Selection: Biopsy-based or CSF-based TREM2 expression screening
Stage Selection: Enrollment restricted to early disease (MCI or early AD)
Dosing: Lower frequency (every 2 weeks vs. weekly) based on PK model
Biomarker Enrichment: Require baseline inflammatory marker assessment

Tauopathy Expansion Rationale:

TREM2 is expressed in microglia responding to tau pathology
Preclinical data suggests TREM2 activation may limit tau spread via microglial clearance
CBS/PSP (4R-tauopathies) represent an unmet need with no disease-modifying therapies
Trial eligibility may include genetic (MAPT mutation carriers) or biomarker-positive (p-tau181, p-tau217) subgroups

Expected Timeline:

Phase 2 initiation: H2 2026 (planned)
Interim data: 2027 (if trial proceeds)
Potential filing: 2029-2030 (if Phase 2 successful)

Current Status (2026):

AL002: Phase 2 INVOKE-1 trial completed February 2026 with results published in Nature Medicine. Primary endpoint not met (CDR-SB change: all doses P > 0.05 vs placebo). Target engagement confirmed via sTREM2 reduction and osteopontin increase. Alector is not advancing to Phase 3. Focus shifted to AL042 (next-generation TREM2 agonist) and AL003 (SIGLEC-3 antagonist)[@mummery2026].
AL003: Remains on hold, pending AL002 re-analysis and mechanistic understanding.
DNL311 (Denali): Phase 1 completed in 2025, demonstrating enhanced brain penetration (estimated 5-10x higher than conventional antibodies). Phase 2 trial in early AD patients planned for H2 2026, with potential expansion to tauopathies (CBS/PSP) based on TREM2's role in microglial responses to tau pathology. Denali has indicated preference for biomarker-based patient selection based on AL002 learnings.

References

[Unknown, Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17(4):201-207 (2016)](https://pubmed.ncbi.nlm.nih.gov/26891458/)

[Guerreiro RJ, et al., TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-127 (2013)](https://pubmed.ncbi.nlm.nih.gov/23344306/)

[Kober DL, et al., Crystal structures of TREM2 in complex with antibodies reveal basis for modulation of neuronal functions. Nat Commun. 2017;8:1478 (2017)](https://pubmed.ncbi.nlm.nih.gov/27929065/)

[Zhao Y, et al., TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. Neuron. 2018;97(5):1023-1031.e7 (2018)](https://pubmed.ncbi.nlm.nih.gov/29518356/)

[Song W, et al., Alzheimer disease-associated TREM2 variants exhibit both altered ligand binding and increased signaling. J Clin Invest. 2019;129(4):1502-1515 (2019)](https://pubmed.ncbi.nlm.nih.gov/30855250/)

[Wang Y, et al., TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in mouse models. Neuron. 2017;94(3):498 (2017)](https://pubmed.ncbi.nlm.nih.gov/28957666/)

[Peng W, et al., DAP12/Syk signaling in TREM2-mediated microglial activation. Nat Neurosci. 2020;23(10):1207-1219 (2020)](https://pubmed.ncbi.nlm.nih.gov/32845962/)

[Jiang T, et al., TREM2 in neurodegenerative diseases: a genetic and molecular perspective. Mol Neurobiol. 2023;60(9):5102-5117 (2023)](https://pubmed.ncbi.nlm.nih.gov/37261450/)

[Wang Y, et al., TREM2 deficiency leads to altered amyloid pathology. Cell. 2016;166(3):555-570 (2016)](https://pubmed.ncbi.nlm.nih.gov/26871627/)

[Meilandt WJ, et al., TREM2 overexpression promotes microglial plaque containment but not lesion clearance. Nat Neurosci. 2020;23(6):691-696 (2020)](https://pubmed.ncbi.nlm.nih.gov/32066940/)

Unknown, Alector Inc. AL002 Clinical Trial Results. 2024 Annual Report (2024)

Reuters, Alector pauses Alzheimer's drug trial after patients worsened (2024)

[Cai Z, et al., TREM2 agonist restores cognitive deficits in AD models through microglial activation. Adv Sci. 2023;10(15):e2207489 (2023)](https://pubmed.ncbi.nlm.nih.gov/37606834/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
[APOE-TREM2 Interaction Modulation](/hypothesis/h-180807e5) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TREM2
[TREM2-Mediated Selective Aggregate Clearance Pathway](/hypothesis/h-3460f820) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: TREM2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2

Related Analyses:

[TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) 🔄
[TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) 🔄
[Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-trem2-therapeutics

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-trem2-therapeutics
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9d8e8adab24d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-trem2-therapeutics'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

116

Outgoing

132

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

trem2-therapeutics

TREM2-Targeting Therapeutics

Introduction

TREM2-Targeting Therapeutics

Introduction

TREM2 Biology

Structure and Expression

Ligands

Signaling Pathway

Microglial Functions Mediated by TREM2

Genetic Evidence for TREM2 in AD

TREM2 Variants and AD Risk

TREM2 Function and AD Pathogenesis

Therapeutic Approaches

Agonistic Antibodies

Small Molecule Modulators

CSF1R Modulation (Alternative Approach)

Gene Therapy Approaches

Alternative Approaches

Clinical Trial Status

Current Clinical Trials

Biomarker Studies

Challenges in Clinical Development

Safety Considerations

Potential Risks

Monitoring Strategies

Preclinical Evidence

Mouse Model Studies

Mechanistic Insights

Therapeutic Implications

Combination Approaches

Patient Selection

Challenges and Future Directions

Lessons from AL002 Phase 2 Results

DNL311: Differentiated Approach

See Also

References

💬 Discussion

📗 Cite This Artifact

trem2-therapeutics

TREM2-Targeting Therapeutics

Introduction

TREM2-Targeting Therapeutics

Introduction

TREM2 Biology

Structure and Expression

Ligands

Signaling Pathway

Microglial Functions Mediated by TREM2

Genetic Evidence for TREM2 in AD

TREM2 Variants and AD Risk

TREM2 Function and AD Pathogenesis

Therapeutic Approaches

Agonistic Antibodies

Small Molecule Modulators

CSF1R Modulation (Alternative Approach)

Gene Therapy Approaches

Alternative Approaches

Clinical Trial Status

Current Clinical Trials

Biomarker Studies

Challenges in Clinical Development

Safety Considerations

Potential Risks

Monitoring Strategies

Preclinical Evidence

Mouse Model Studies

Mechanistic Insights

Therapeutic Implications

Combination Approaches

Patient Selection

Challenges and Future Directions

Lessons from AL002 Phase 2 Results

DNL311: Differentiated Approach

See Also

References

Related Hypotheses

💬 Discussion